Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation

This study has been completed.

Sponsor:

ClinicalTrials.gov Identifier:

NCT00219583

First Posted: September 22, 2005

Last Update Posted: November 7, 2012

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Information provided by (Responsible Party):

Pfizer

Purpose

Assessment of efficacy and safety UK-390,957.

Condition	Intervention	Phase
Ejaculation	Drug: UK-390,957	Phase 2 Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment
Official Title:	A Phase 2b, Multi-Centre, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study To Assess The Efficacy and Safety Of Oral UK390,957 In Men With Premature Ejaculation

Further study details as provided by Pfizer:

Primary Outcome Measures:

Assessment of efficacy and safety

Secondary Outcome Measures:

Assessment of quality of sexual life


Estimated Enrollment:	460
Study Start Date:	August 2004
Study Completion Date:	June 2005
Primary Completion Date:	June 2005 (Final data collection date for primary outcome measure)

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Premature ejaculation as defined by DSM-IV

Exclusion Criteria:

History of erectile dysfunction

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00219583

Show 50 Study Locations

Sponsors and Collaborators

Pfizer

Investigators


Study Director:	Pfizer CT.gov Call Center	Pfizer

More Information

Additional Information:

To obtain contact information for a study center near you, click here. This link exits the ClinicalTrials.gov site


Responsible Party:	Pfizer
ClinicalTrials.gov Identifier:	NCT00219583 History of Changes
Other Study ID Numbers:	A3871027
First Submitted:	September 9, 2005
First Posted:	September 22, 2005
Last Update Posted:	November 7, 2012
Last Verified:	November 2012

Additional relevant MeSH terms:


Premature Ejaculation Sexual Dysfunction, Physiological Genital Diseases, Male Sexual Dysfunctions, Psychological Mental Disorders

To Top